370 related articles for article (PubMed ID: 28093480)
1. Comprehensive screening for PD-L1 expression in thyroid cancer.
Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
[TBL] [Abstract][Full Text] [Related]
8. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
9. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
10. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
[TBL] [Abstract][Full Text] [Related]
11. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
12. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.
Begum S; Rosenbaum E; Henrique R; Cohen Y; Sidransky D; Westra WH
Mod Pathol; 2004 Nov; 17(11):1359-63. PubMed ID: 15195111
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
16. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
17. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
19. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
